Rafa Laboratories Ltd.
RAFA.TA
Tel Aviv Stock Exchange1,789.00
ILA
-22.00
- -
Rafa Laboratories Ltd.
RAFA.TA
(Tel Aviv Stock Exchange)
Recent
price
1,789.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rafa Laboratories Ltd. develops, manufactures, markets and distributes branded and generic pharmaceutical products, prescription medicines, over-the-counter medicines and therapeutic products in Israel and selected international markets. Founded in 1937, the Israel-based company operates an advanced pharmaceutical manufacturing facility in Har Hotzvim, Jerusalem, and supplies medicines and medical products to healthcare institutions, physicians, pharmacies and patients across Israel. Its product portfolio comprises more than 100 pharmaceutical and therapeutic products, including treatments for obesity; women’s health; dermatology; respiratory and allergy conditions; depression and sleep disorders; pain; gastrointestinal disorders; and pediatric care; as well as hospital-oriented solutions and specialty medicines. Key branded products include Hedrin Once and Hedrin Wash for head-lice treatment and removal; Bondormin for sleep disorders; Stopit for diarrhea; Vaben for anxiety; Daybue for Rett syndrome; Monurol for urinary-tract infections; and Tzalin, an over-the-counter plant-based product for allergic rhinitis, nasal congestion and related eye and throat symptoms. Rafa also provides market-access, commercialization, manufacturing, marketing and distribution capabilities to domestic and international pharmaceutical partners seeking to enter the Israeli market. The company operates through pharmaceutical production and sales and biodefense activities. Its biodefense business develops and supplies autoinjector-based medical countermeasures for emergency use against chemical-warfare and atomic, biological and chemical threats, and advances products addressing trauma, pain and severe hemorrhage. Rafa has received funding support of up to USD 186 million from the U.S. Department of Health and Human Services for development of a tranexamic-acid injection intended to treat severe traumatic hemorrhaging. In June 2026, the company secured a USD 46 million atropine supply agreement with the U.S. Administration for Strategic Preparedness and Response, expanding its medical-countermeasure operations. In March 2025, Rafa launched Hedrin Wash shampoo, a five-minute hair-wash product designed to eliminate head lice and remove lice eggs. In July 2026, Rafa completed a Tel Aviv Stock Exchange offering of 34.78 million ordinary shares and attached warrants, raising approximately NIS 549.9 million; the transaction included sales by controlling shareholder FIMI Opportunity Funds, which acquired control of Rafa from the Sackler family in 2020.